Online citations, reference lists, and bibliographies.
← Back to Search

A Cost‐utility Analysis Of Treatment For Acute Childhood Idiopathic Thrombocytopenic Purpura (ITP)

S. O'Brien, A. K. Ritchey, Kenneth J. Smith
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The primary objective in the treatment of acute pediatric idiopathic thrombocytopenic purpura (ITP) is to rapidly increase the platelet count.
This paper references
[Intracranial hemorrhage in idiopathic thrombocytopenic purpura (ITP) (author's transl)].
I. Mutz (1976)
10.1136/jech.41.4.355-a
Methods for the economic evaluation of health care programmes
S. Wilson (1987)
10.1016/S0022-3476(88)80654-1
Pulse methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura.
J. van Hoff (1988)
Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group Study.
A. Dubansky (1989)
10.1016/S0022-3476(05)80400-7
A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.
V. Blanchette (1993)
10.1136/bmj.307.6908.859
Cost-utility analysis.
R. Robinson (1993)
10.3109/08880019309029508
Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
S. Ozsoylu (1993)
10.1159/000204392
Idiopathic thrombocytopenic purpura in Egyptian children.
A. Khalifa (1993)
10.1016/S0140-6736(94)92205-5
Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura
V. Blanchette (1994)
10.1136/ADC.71.3.251
Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology.
J. Lilleyman (1994)
10.1016/S0022-3476(05)82024-4
Acute immune thrombocytopenic purpura: a comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulin.
D. Albayrak (1994)
10.1001/JAMA.1996.03540150055031
Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
M. Weinstein (1996)
10.1111/j.1651-2227.1996.tb14183.x
Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura
S. Rosthøj (1996)
10.1182/BLOOD.V88.1.3.BLOODJOURNAL8813
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
J. George (1996)
Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40
JN George (1996)
Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the
J N George (1996)
10.1097/00043426-199705000-00004
Safety and Efficacy of Low‐Dose Intravenous Immune Globulin (IVIG) Treatment for Infants and Children with Immune Thrombocytopenic Purpura
I. Warrier (1997)
10.1097/00005650-199806000-00002
Toward consistency in cost-utility analyses: using national measures to create condition-specific values.
M. Gold (1998)
Safety profile of WinRho anti-D.
F. Hong (1998)
10.1111/j.1651-2227.1998.tb01239.x
Short‐course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP)
M. Carcao (1998)
Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children.
A. Freiberg (1998)
Toward consistency in costutility analysis: Using national measures to create conditionspecific
MR Gold (1998)
10.1016/S0022-3476(99)70367-7
Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.
M. Tarantino (1999)
10.1177/0272989X0002000310
Willingness to Pay for a Quality-adjusted Life Year
R. Hirth (2000)
A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura.
K. Fujisawa (2000)
10.1002/(SICI)1096-8652(200003)63:3<156::AID-AJH9>3.0.CO;2-4
The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin
S. G. Sandler (2000)
10.1016/S1352-0237(00)00164-7
Bureau of Labor Statistics Web Site
J. Desposito (2000)
10.1097/00043426-200111000-00009
Initial Bone Marrow Aspiration in Childhood Idiopathic Thrombocytopenia: Decision Analysis
R. Klaassen (2001)
10.1055/S-2001-15257
Outcome measures and treatment endpoints other than platelet count in childhood idiopathic thrombocytopenic purpura.
G. Buchanan (2001)
10.1016/S0140-6736(01)07219-1
Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study
T. Kühne (2001)
10.1046/j.1365-2141.2001.02627.x
A dose of 75 μg/kg/d of i.v. anti‐D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura
G. Newman (2001)
A dose of 75 mcg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 mcg/kg/d in adults with immune thrombocytopenic purpura
GC Newman (2001)
Initial bonemarrow aspirate in childhood idiopathic thrombocytopenic purpura: Decision analysis
KlassenRJ (2001)
10.1080/08880010290097161
ANTI-D EXERTS A VERY EARLY RESPONSE IN CHILDHOOD ACUTE IDIOPATHIC THROMBOCYTOPENIC PURPURA
A. Moser (2002)
10.1080/08880010252899370
CLINICAL COURSE OF CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA TREATED WITH INTRAVENOUS IMMUNOGLOBULIN G OR MEGADOSE METHYLPREDNISOLONE OR OBSERVED WITHOUT THERAPY
F. Duru (2002)
10.1097/00043426-200210000-00008
Randomized Trial of High-Dose Methylprednisolone Versus Intravenous Immunoglobulin for the Treatment of Acute Idiopathic Thrombocytopenic Purpura in Children
K. G. Ancona (2002)
A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura.
E. Erduran (2003)
10.1097/00043426-200302000-00009
Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001
S. Vesely (2003)
10.1055/S-2004-815628
Childhood acute immune thrombocytopenic purpura: 20 years later.
V. Blanchette (2003)
High-dose anti-D immune globulin is as effective as IVIG in the treatment of newly diagnosed immune thrombocytopenic purpura (ITP) in children
MD Tarantino (2003)
10.1002/AJH.20295
Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura
Manjusha Kumar (2005)
Treatment, outcome, and cost of care in childrenwith idiopathic thrombocytopenic purpura
KumarM (2005)
10.1200/jop.2006.2.6.313
The American Society of Pediatric Hematology/Oncology.
N. Seibel (2006)
From the Centers for Medicare and Medicaid Services web site



This paper is referenced by
10.1007/s12098-019-03155-4
Immune Thrombocytopenia in Children: Consensus and Controversies
Gurpreet Singh (2020)
10.1002/ccr3.1916
Eltrombopag in long‐term management of pediatric thrombocytopenia
S. Shah (2019)
10.1016/J.CPEM.2018.05.007
Breaking Down Blood: Pediatric Immune Thrombocytopenia and Autoimmune Hemolytic Anemia in the Emergency Department
Richard T Graham (2018)
10.1097/MPH.0000000000001247
A Quality Improvement Bundle to Improve Informed Choice for Children With Typical, Newly Diagnosed Immune Thrombocytopenia
C. Beck (2018)
10.1080/14728214.2017.1294158
Emerging drugs for immune thrombocytopenia (ITP)
A. Salama (2017)
10.1053/j.seminhematol.2016.04.019
Anti-D treatment for pediatric immune thrombocytopenia: Is the bad reputation justified?
J. Yacobovich (2016)
10.4274/tjh.2014.0436
Platelet Levels of High- and Mega-Dose Methylprednisolone Treatment in Acute Immune Thrombocytopenia
Ali Ayçiçek (2015)
Membrane forces and key protein determinants of hematopoietic cell function: Lamins and myosin-II in hematopoiesis and CD47 in immunotherapy of cancer
K. Spinler (2014)
10.1007/s40273-014-0171-9
A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding
R. Sruamsiri (2014)
10.1002/pbc.24633
Anti‐D immunoglobulin therapy for pediatric ITP: Before and after the FDA's black box warning
Joel C. Thompson (2013)
10.1542/peds.2012-2021
Patterns of Inpatient Care for Newly Diagnosed Immune Thrombocytopenia in US Children’s Hospitals
Courtney Kime (2013)
thrombocytopenic purpura Severe hemorrhage in children with newly diagnosed immune
J. Neufeld (2013)
Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
G. Blackhouse (2012)
10.3111/13696998.2011.646045
Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue
M. Iskedjian (2012)
Five things physicians and patients should question.
(2012)
10.1177/0272989X11400417
Decision Modeling of Disagreements
H. Lehmann (2011)
10.1007/s00277-010-0930-4
Evaluating bleeding severity in immune thrombocytopenia (ITP)
C. Neunert (2010)
10.1007/springerreference_73517
188 Quality of Life in Immune Thrombocytopenic Purpura: China Perspectives
R. Yang (2010)
10.1016/j.hoc.2009.11.004
Childhood immune thrombocytopenic purpura: diagnosis and management.
V. Blanchette (2010)
10.1093/tropej/fmq022
Short-course high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in children.
Dinesh Kumar Yadav (2010)
10.1111/j.1365-2141.2009.08057.x
Comparison of intravenous immune globulin and high dose anti‐D immune globulin as initial therapy for childhood immune thrombocytopenic purpura
I. Kane (2010)
10.1002/pbc.22708
A cost‐effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children
J. Cooper (2010)
Canadian Agency for Drugs and Technologies in Health Intravenous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy : Clinical-and Cost-Effectiveness Analyses
K. Gaebel (2009)
10.1002/pbc.21978
Relationships among bleeding severity, health‐related quality of life, and platelet count in children with immune thrombocytopenic purpura
C. Neunert (2009)
10.26719/2009.15.3.729
Immune thrombocytopenia in children with reference to low-income countries.
A. Rehman (2009)
10.1002/pbc.21231
How far should we go with cost‐utility analysis when treating children with acute idiopathic thrombocytopenic purpura?
M. Benesch (2008)
Canadian Agency for Drugs and Technologies in Health Intravenous Immunoglobulin for Treatment of Idiopathic Thrombocytopenic Purpura : Economic and Health Service Impact Analyses
G. Blackhouse (2008)
Rituximab in the treatment of autoimmune haematological disorders
St Michael’s (2008)
10.1182/blood-2008-03-138487
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.
C. Neunert (2008)
10.1016/j.pcl.2008.01.009
Childhood immune thrombocytopenic purpura: diagnosis and management.
V. Blanchette (2008)
10.1111/j.1365-2141.2008.07054.x
Rituximab in the treatment of autoimmune haematological disorders
B. Garvey (2008)
10.1016/j.pcl.2008.01.004
Decision analysis in pediatric hematology.
S. O'Brien (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar